Format

Send to

Choose Destination
Ann Surg Oncol. 2017 Mar;24(3):660-668. doi: 10.1245/s10434-016-5583-7. Epub 2016 Oct 4.

Clinical Utility of the 12-Gene DCIS Score Assay: Impact on Radiotherapy Recommendations for Patients with Ductal Carcinoma In Situ.

Author information

1
The Christ Hospital Health Network, Cincinnati, OH, USA. Jennifer.Manders@thechristhospital.com.
2
University of Texas MD Anderson Cancer Center, Houston, TX, USA.
3
The Christ Hospital Health Network, Cincinnati, OH, USA.
4
Ohio State University James Cancer Hospital, Columbus, OH, USA.
5
Bryn Mawr Hospital, Bryn Mawr, PA, USA.
6
Rocky Mountain Cancer Centers, Denver, CO, USA.
7
Rochester Regional Health System, Rochester, NY, USA.
8
Saint Elizabeth Medical Center, Inc., Edgewood, KY, USA.
9
UF Health Cancer Center at Orlando Health, Orlando, FL, USA.
10
Stanford Cancer Institute, Stanford University, Palo Alto, CA, USA.
11
Yale University, New Haven, CT, USA.
12
Advocate Christ Medical Center, Oak Lawn, IL, USA.
13
Louisiana State University Health New Orleans, New Orleans, LA, USA.
14
Albert Einstein Healthcare Network, Philadelphia, PA, USA.
15
Beth Israel Deaconess Medical Center, Boston, MA, USA.
16
Genomic Health, Inc., Redwood City, CA, USA.
17
Duke University Medical Center, Durham, NC, USA.

Abstract

OBJECTIVE:

The aim of this study was to determine the impact of the results of the 12-gene DCIS Score assay on (i) radiotherapy recommendations for patients with pure ductal carcinoma in situ (DCIS) following breast-conserving surgery (BCS), and (ii) patient decisional conflict and state anxiety.

METHODS:

Thirteen sites across the US enrolled patients (March 2014-August 2015) with pure DCIS undergoing BCS. Prospectively collected data included clinicopathologic factors, physician estimates of local recurrence risk, DCIS Score results, and pre-/post-assay radiotherapy recommendations for each patient made by a surgeon and a radiation oncologist. Patients completed pre-/post-assay decisional conflict scale and state-trait anxiety inventory instruments.

RESULTS:

The analysis cohort included 127 patients: median age 60 years, 80 % postmenopausal, median size 8 mm (39 % ≤5 mm), 70 % grade 1/2, 88 % estrogen receptor-positive, 75 % progesterone receptor-positive, 54 % with comedo necrosis, and 18 % multifocal. Sixty-six percent of patients had low DCIS Score results, 20 % had intermediate DCIS Score results, and 14 % had high DCIS Score results; the median result was 21 (range 0-84). Pre-assay, surgeons and radiation oncologists recommended radiotherapy for 70.9 and 72.4 % of patients, respectively. Post-assay, 26.4 % of overall recommendations changed, including 30.7 and 22.0 % of recommendations by surgeons and radiation oncologists, respectively. Among patients with confirmed completed questionnaires (n = 32), decision conflict (p = 0.004) and state anxiety (p = 0.042) decreased significantly from pre- to post-assay.

CONCLUSIONS:

Individualized risk estimates from the DCIS Score assay provide valuable information to physicians and patients. Post-assay, in response to DCIS Score results, surgeons changed treatment recommendations more often than radiation oncologists. Further investigation is needed to better understand how such treatment changes may affect clinical outcomes.

PMID:
27704370
PMCID:
PMC5306072
DOI:
10.1245/s10434-016-5583-7
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Springer Icon for PubMed Central
Loading ...
Support Center